Daruna JH, Barnes PA. A neurodevelopmental view of impulsivity. In: McCown WG, Johnson J, Shure MB (eds). The Impulsive Client: Theory, Research, and Treatment. American Psychological Association: Washington, DC, USA, 1993, pp 23–37.
Nigg JT, Wong MM, Martel MM, Jester JM, Puttler LI, Glass JM et al. Poor response inhibition as a predictor of problem drinking and illicit drug use in adolescents at risk for alcoholism and other substance use disorders. J Am Acad Child Adolesc Psychiatry 2006; 45: 468–475.
Tarter RE, Kirisci L, Mezzich A, Cornelius JR, Pajer K, Vanyukov M et al. Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder. Am J Psychiatry 2003; 160: 1078–1085.
Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008; 320: 1352–1355.
Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315: 1267–1270.
Diergaarde L, Pattij T, Poortvliet I, Hogenboom F, de Vries W, Schoffelmeer AN et al. Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biol Psychiatry 2008; 63: 301–308.
Perry JL, Nelson SE, Carroll ME. Impulsive choice as a predictor of acquisition of IV cocaine self- administration and reinstatement of cocaine-seeking behavior in male and female rats. Exp Clin Psychopharmacol 2008; 16: 165–177.
Zeng H, Lee TM, Waters JH, So KF, Sham PC, Schottenfeld RS et al. Impulsivity, cognitive function, and their relationship in heroin-dependent individuals. J Clin Exp Neuropsychol 2013; 35: 897–905.
Peles E, Schreiber S, Sutzman A, Adelson M. Attention deficit hyperactivity disorder and obsessive-compulsive disorder among former heroin addicts currently in methadone maintenance treatment. Psychopathology 2012; 45: 327–333.
Dissabandara LO, Loxton NJ, Dias SR, Dodd PR, Daglish M, Stadlin A. Dependent heroin use and associated risky behaviour: the role of rash impulsiveness and reward sensitivity. Addict Behav 2014; 39: 71–76.
SAMHSABehavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Office of Applied Studies, NSDUH Series H-50, HHS Publication No. SMA 15-4927: Rockville, MD, USA, 2015.
Dalley JW, Mar AC, Economidou D, Robbins TW. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav 2008; 90: 250–260.
Bechara A, Van Der Linden M. Decision-making and impulse control after frontal lobe injuries. Curr Opin Neurol 2005; 18: 734–739.
Cardinal RN, Pennicott DR, Sugathapala CL, Robbins TW, Everitt BJ. Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 2001; 292: 2499–2501.
Jentsch JD, Ashenhurst JR, Cervantes MC, Groman SM, James AS, Pennington ZT. Dissecting impulsivity and its relationships to drug addictions. Ann N Y Acad Sci 2014; 1327: 1–26.
da Costa Araujo S, Body S, Hampson CL, Langley RW, Deakin JF, Anderson IM et al. Effects of lesions of the nucleus accumbens core on inter-temporal choice: further observations with an adjusting-delay procedure. Behav Brain Res 2009; 202: 272–277.
Pothuizen HH, Jongen-Relo AL, Feldon J, Yee BK. Double dissociation of the effects of selective nucleus accumbens core and shell lesions on impulsive-choice behaviour and salience learning in rats. Eur J Neurosci 2005; 22: 2605–2616.
Sesia T, Temel Y, Lim LW, Blokland A, Steinbusch HW, Visser-Vandewalle V. Deep brain stimulation of the nucleus accumbens core and shell: opposite effects on impulsive action. Exp Neurol 2008; 214: 135–139.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 2009; 56(Suppl 1): 18–31.
Stefanik MT, Moussawi K, Kupchik YM, Smith KC, Miller RL, Huff ML et al. Optogenetic inhibition of cocaine seeking in rats. Addict Biol 2013; 18: 50–53.
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40(Database issue): D930–D934.
Albertson DN, Schmidt CJ, Kapatos G, Bannon MJ. Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology 2006; 31: 2304–2312.
Jacobs MM, Okvist A, Horvath M, Keller E, Bannon MJ, Morgello S et al. Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels. Mol Psychiatry 2013; 18: 1205–1210.
Drakenberg K, Nikoshkov A, Horvath MC, Fagergren P, Gharibyan A, Saarelainen K et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci USA 2006; 103: 7883–7888.
Edenberg HJ, Bierut LJ, Boyce P, Cao M, Cawley S, Chiles R et al. Description of the data from the Collaborative Study on the Genetics of Alcoholism (COGA) and single-nucleotide polymorphism genotyping for Genetic Analysis Workshop 14. BMC Genet 2005; 6(Suppl 1): S2.
Rajendran K, Rindskopf D, O'Neill S, Marks DJ, Nomura Y, Halperin JM. Neuropsychological functioning and severity of ADHD in early childhood: a four-year cross-lagged study. J Abnorm Psychol 2013; 122: 1179–1188.
Trampush JW, Jacobs MM, Hurd YL, Newcorn JH, Halperin JM. Moderator effects of working memory on the stability of ADHD symptoms by dopamine receptor gene polymorphisms during development. Dev Sci 2014; 17: 584–595.
Schumann G, Loth E, Banaschewski T, Barbot A, Barker G, Buchel C et al. The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry 2010; 15: 1128–1139.
Jutras-Aswad D, Jacobs MM, Yiannoulos G, Roussos P, Bitsios P, Nomura Y et al. Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin SNPs associated with amygdala gene expression: case-controlstudy. PLoS ONE 2012; 7: e39243.
Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry 2010; 15: 1053–1066.
Carlezon WA Jr, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005; 28: 436–445.
Laoide BM, Foulkes NS, Schlotter F, Sassone-Corsi P. The functional versatility of CREM is determined by its modular structure. EMBO J 1993; 12: 1179–1191.
Rauen T, Hedrich CM, Tenbrock K, Tsokos GC. cAMP responsive element modulator: a critical regulator of cytokine production. Trends Mol Med 2013; 19: 262–269.
Maldonado R, Smadja C, Mazzucchelli C, Sassone-Corsi P. Altered emotional and locomotor responses in mice deficient in the transcription factor CREM. Proc Natl Acad Sci USA 1999; 96: 14094–14099.
Wallis D, Hill DS, Mendez IA, Abbott LC, Finnell RH, Wellman PJ et al. Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res 2012; 1463: 85–92.
Ranaivoson FM, Liu Q, Martini F, Bergami F, von Daake S, Li S et al. Structural and mechanistic insights into the Latrophilin3-FLRT3 complex that mediates glutamatergic synapse development. Structure 2015; 23: 1665–1677.
Lange M, Norton W, Coolen M, Chaminade M, Merker S, Proft F et al. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. Mol Psychiatry 2012; 17: 946–954.